The burden of mental, neurological, and substance use (MNS) disorders increased by 41% between 1990 and 2010 and now accounts for one in every 10 lost years of health globally. This sobering statistic does not take into account the substantial excess mortality associated with these disorders or the social and economic consequences of MNS disorders on aff ected persons, their caregivers, and society. A wide variety of eff ective interventions, including drugs, psychological treatments, and social interventions, can prevent and treat MNS disorders. At the population-level platform of service delivery, best practices include legislative measures to restrict access to means of self-harm or suicide and to reduce the availability of and demand for alcohol. At the community-level platform, best practices include life-skills training in schools to build social and emotional competencies. At the health-care-level platform, we identify three delivery channels. Two of these delivery channels are especially relevant from a public health perspective: self-management (eg, web-based psychological therapy for depression and anxiety disorders) and primary care and community outreach (eg, non-specialist health worker delivering psychological and pharmacological management of selected disorders). The third delivery channel, hospital care, which includes specialist services for MNS disorders and fi rst-level hospitals providing other types of services (such as general medicine, HIV, or paediatric care), play an important part for a smaller proportion of cases with severe, refractory, or emergency presentations and for the integration of mental health care in other health-care channels, respectively. The costs of providing a signifi cantly scaled up package of specifi ed cost-eff ective interventions for prioritised MNS disorders in low-income and lower-middle-income countries is estimated at US$3-4 per head of population per year. Since a substantial proportion of MNS disorders run a chronic and disabling course and adversely aff ect household welfare, intervention costs should largely be met by government through increased resource allocation and fi nancial protection measures (rather than leaving households to pay out-ofpocket). Moreover, a policy of moving towards universal public fi nance can also be expected to lead to a far more equitable allocation of public health resources across income groups. Despite this evidence, less than 1% of development assistance for health and government spending on health in low-income and middle-income countries is allocated to the care of people with these disorders. Achieving the health gains associated with prioritised interventions will require not just fi nancial resources, but committed and sustained eff orts to address a range of other barriers (such as paucity of human resources, weak governance, and stigma). Ultimately, the goal is to massively increase opportunities for people with MNS disorders to access services without the prospect of discrimination or impoverishment and with the hope of attaining optimal health and social outcomes.
Introduction
The primary goal of Disease Control Priorities in Developing Countries, fi rst published by the World Bank in 1993, is to synthesise evidence of the burden of specifi c health disorders and, more importantly, the relative eff ectiveness and cost-eff ectiveness of interventions so as to assist decision makers in allocating often tightly constrained budgets and ensuring that health system objectives are maximally achieved. The third edition of Disease Control Priorities (DCP-3) aims to provide up-to-date evidence and includes several novel features that build on previous editions, for example by addressing how interventions can be packaged together across a range of delivery platforms and channels (appendix p 1). 1 Here we describe the key fi ndings of the evidence related to mental, neurological, and substance use (MNS) disorders.
MNS disorders are a heterogeneous range of disorders that owe their origin to a complex array of genetic, biological, psychological, and social factors. Although many health systems deliver care for these disorders through separate channels, with an emphasis on specialist services in hospitals, the disorders have been grouped together here because they share several important characteristics, notably: all owe their symptoms and impairments to some degree of brain dysfunction; social determinants play an important part in the aetiology and symptom expression (panel 1); 2,3 they frequently co-occur in the same individual; their eff ect on families and wider society is profound; they are strongly associated with stigma and discrimination; they often take a chronic or relapsing course; and they all share a pitifully inadequate response from health-care systems in all countries, but particularly in low-income and middle-income countries. This grouping is also consistent with the DCP-3 goals of synthesising evidence and making recommendations across diverse health disorders and with WHO's Mental Health Gap Action Programme (mhGAP). 4 (Prof R Laxminarayan PhD); Princeton Environmental Institute, Princeton University, Princeton, NJ, USA (Prof R Laxminarayan); Public Health Foundation of India, In DCP-3, we have considered interventions for fi ve groups of disorders (adult mental disorders, child mental and developmental disorders, neurological disorders, alcohol use disorder, and illicit drug use disorders) and for suicide and self-harm, a health outcome strongly associated with MNS disorders. Within each group, we have prioritised disorders that are associated with high burden and for which evidence exists in support of interventions that are cost eff ective and scalable. Inevitably, such an approach does not address a substantial number of disorders (eg, multiple sclerosis as a neurological disorder and anorexia nervosa as an adult mental disorder), but our recommendations could be extended to several other disorders that have not been expressly addressed, in particular with respect to the delivery of packages for care. Additionally, some important MNS disorders or concerns are covered in other volumes of the DCP-3 series, notably, nicotine dependence, early child development, neurological infections, and stroke.
In this report, we address fi ve themes. First, we address the question of why MNS disorders deserve prioritisation by pointing to and reviewing the health and economic burden of disease attributable to MNS disorders. Second, we review the evidence of the eff ectiveness of specifi c interventions for the prevention and treatment of the selected MNS disorders. Third, we consider how and where these interventions can be appropriately implemented across a range of service delivery platforms. Fourth, we examine the cost of scaling up cost-eff ective interventions and the case for enhanced service coverage and fi nancial protection for people with MNS disorders. Finally, we consider the barriers and strategies for successful scale-up.
Why MNS disorders matter for global health
The Global Burden of Disease Study 2010 (GBD 2010) 5 identifi ed MNS disorders as signifi cant causes of the world's disease burden. We use GBD 2010 data to investigate trends in the burden due to MNS disorders. Between 1990 and 2010, absolute disability-adjusted life-years (DALYs) due to MNS disorders rose by 41%, from 182 million DALYs to 258 million DALYs (the proportion of global disease burden increased from 7·3% to 10·4%). With the exception of substance use disorders, which increased in prevalence with time, this increase in MNS-related DALYs was largely due to population growth and ageing. As a group, MNS disorders were the leading cause of years lived with disability (YLDs) globally (fi gure 1). DALYs from MNS disorders were highest during early-to-mid-adulthood, explaining 18·6% of total DALYs in individuals aged years as opposed to 10·4% at all ages combined. DALYs from neurological disorders were highest in elderly people. The burden of these disorders contains important gender diff erences: men accounted for more DALYs from mental disorders occurring in childhood, schizophrenia, substance use disorders, Parkinson's disease, and epilepsy, whereas more DALYs accrue to women for all other disorders in this group. The relative proportion of DALYs from MNS disorders to overall disease burden was estimated to be 1·6 times higher in developed regions (15·5% of total DALYs) than in The causal mechanisms of the social determinants of MNS disorders indicate a cyclical pattern: on one hand, socioeconomic adversities increase risk for MNS disorders (the social causation pathway); on the other hand, people living with MNS disorders drift into poverty during the course of their life through increased health-care expenditure, reduced economic productivity associated with disability, and stigma and discrimination associated with these disorders (the social drift pathway).
Understanding the vicious cycle of social determinants and MNS disorders provides opportunities for interventions that target both social causation and social drift. In relation to social causation, the evidence for the mental health benefi ts of poverty alleviation interventions is mixed but growing. In relation to social drift, the evidence for the individual and household economic benefi ts of MNS disorder prevention and treatment is compelling, and supports the economic argument for scaling up these interventions. 3 developing regions (9·4% of total DALYs), largely due to the relatively higher burden of other health disorders such as infectious and perinatal diseases in developing regions. Because of the larger population in low-income and middle-income countries, however, absolute DALYs from MNS disorders are higher than in high-income countries. Burden due to premature mortality according to GBD 2010 might incorrectly lead to the interpretation that premature death in people with MNS disorders is inconsequential. This is because of how causes of deaths are assigned in the International Classifi cation of Diseases (ICD) death-coding system used by GBD 2010. Yet, evidence shows that people with MNS disorders have a signifi cant reduction in life expectancy, with risk of mortality increasing with disorder severity. [8] [9] [10] Consequently, we also explore diff erences between GBD 2010 estimates of cause-specifi c and excess mortality from these disorders and potential contributors to life-expectancy gaps. Although reported years of life lost (YLLs) accounted for only 15·3% of DALYs from MNS disorders, equivalent to 840 000 deaths, natural history models generated by DisMod-MR estimate that sub stantially more deaths could be associated with these disorders. 11 Excess deaths from major depression alone were estimated at more than 2·2 million in 2010. This number is signifi cantly higher than other attempts to quantify the same 10 and potentially indicates a much higher degree of mortality associated with MNS disorders than that captured by the assessment of YLLs in GBD 2010. However, because these estimates of excess deaths included deaths from both causal and non-causal origins, they must be interpreted with caution. In relation to excess deaths presented in table 1, comparative risk analyses 12 have also highlighted mental and substance use disorders as signifi cant risk factors of premature death from a range of other health outcomes. For example, an estimated 60% of suicide deaths can be reattributed to mental and substance use disorders, which would elevate them from the fi fth to the third leading cause of burden of disease. 6
Disorder
Cause-specifi c deaths (uncertainty range) Autistic spectrum disorders 0 109 000 (96 000-122 000) Accidents, respiratory diseases, and seizures; comorbid disorders, particularly epilepsy and intellectual disability *In the Global Burden of Disease Study (GBD) 2010, the anxiety disorders category represents any anxiety disorder; although mortality data are available for individual anxiety disorders, estimates of mortality associated with any anxiety disorder required for GBD purposes are not available. †Insuffi cient data are available to derive estimates of excess mortality for disruptive behavioural disorders. ‡In the GBD 2010 cause of death modelling, the mean value for cocaine and amphetamine use disorders falls outside the 95% uncertainty interval. This was because the full distribution of 1000 draws is asymmetric with a long tail and a small number high values in the uncertainty distribution pushes the mean above the 97·5 percentile of distribution. These estimates of disease burden do not fully take into account the substantial social and economic consequences of MNS disorders, not only for aff ected individuals and households but also for communities and economies. Notable examples of such eff ects include that of maternal mental disorders on the wellbeing of their children, contributing to the intergenerational transmission of poor health and poverty; of substance use disorders on criminal behaviour and incarceration; and of a range of severe disorders on the economic productivity of aff ected persons and of family members engaged in caregiving. The total economic output lost to MNS disorders globally in 2010 was estimated to be $8·5 trillion, a sum expected to nearly double by 2030 unless a concerted response is mounted. 13 Economic costs attributable to alcohol use and alcohol use disorders alone are estimated to amount to the equivalent of 1·3-3·3% of gross domestic product (GDP) in a range of high-income and middle-income countries, with more than two-thirds of the loss represented by productivity losses. 14 The global cost of dementia in 2010 has been estimated to be $604 billion, equivalent to 1% of global GDP. 15 Additionally, a rising tide of social adversities are recognised to be associated with MNS disorders, with large and growing proportions of the global population aff ected by confl ict or displacement due to environmental degradation and climate change, which bodes for a grim forecast on the future burden of these disorders. Finally, disease burden estimates do not account for the substantial hazards faced by persons with MNS disorders who face the systematic denial of basic human rights, ranging from limited opportunities for education and employment and extending to torture and denial of freedom, sometimes within health-care institutions. 16
Excess deaths (uncertainty range) Contributors to excess deaths

What works? Eff ective interventions for the prevention and treatment of MNS disorders
The evidence on interventions builds on the recommendations of the second edition of Disease Control Priorities (DCP-2) [17] [18] [19] and is derived from several sources: the mhGAP guidelines developed by WHO for use in non-specialist health settings, which reviewed the literature published up to 2009 using the Grading of Recommendations Assessment, Development and Evaluation (GRADE); 20 other recent reviews where appropriate (eg, Strang and colleagues [2012] 21 for illicit drugs); interventions that required a specialist for delivery, but which had not been addressed by mhGAP or DCP-2, assessed using GRADE; and a review of all reviews, including systematic reviews, and any type of assessment evidence from a low-income and middle-income country published since mhGAP, assessed using GRADE. Our fi ndings are summarised in table 2.
A wide variety of eff ective interventions comprising drug-based, psychological, and social interventions can prevent and treat the range of the priority MNS disorders. As shown in table 2, a set of essential medicines (such as antipsychotic, antidepressant, and antiepileptic drugs) and essential psychosocial interventions (such as cognitive behavioural therapy and parent skills training) can be identifi ed for this group of disorders. Although very few curative interventions for any of these disorders exist, the severity and course of most disorders can be greatly attenuated by psychosocial treatment or generic formulations of essential drugs, including combination drugs tailored to the needs of the individual. A few patients with more severe, refractory, or emergency clinical presentations will need specialist interventions, such as inpatient care with expert nursing for acute psychosis, modifi ed electroconvulsive therapy for severe depression, or surgery for epilepsy. It is important to acknowledge that certain preventive interventions that are primarily intended to target disorders covered in Despite this evidence, a large proportion of persons aff ected by MNS disorders do not have access to these interventions. The poor adoption of eff ective interventions is often aff ected by concerns about fi nancial resources, an issue that is now being addressed by a mounting evidence base in support of the eff ectiveness of delivery by non-specialist health workers 22 as well as their cost-eff ectiveness. 23 A related resource constraint relates to the low availability of appropriately trained mental health workers. Cultural attitudes and beliefs might also pose specifi c barriers; for example, the symptoms associated with depression or anxiety disorders are commonly interpreted as being normative consequences of social adversity, and proven biomedical causal models are rare, leading to low demand for care and low visibility of the disorder from the view of health policy makers and providers. 24 These competing views will clearly aff ect the societal preference for and acceptability of investment in the wider adoption of eff ective interventions for MNS disorders. More generally, stigma, poor awareness, and discrimination are major factors behind the low levels of political commitment and the paucity of demand for care for people with MNS disorders in many populations. 25
How to deliver eff ective interventions?
The implementation of evidence-based interventions for MNS disorders seldom occurs through the delivery of single vertical interventions. More frequently, these interventions are delivered via so-called platforms-the level of the health or welfare system at which interventions or packages can be most appropriately, eff ectively, and effi ciently delivered. A specifi c delivery channel (such as a school or a primary health-care centre) can be viewed as the vehicle for delivery of a particular intervention on a specifi ed platform. Identifi cation of the set of interventions that fall within the realm of a particular delivery channel or platform is of interest and relevance to decision makers because it enables potential opportunities, synergies, and effi ciencies to be identifi ed. The identifi cation of interventions that are relevant for a particular platform also refl ects how resources are often allocated in practice (eg, to schools or primary health-care services rather than to specifi c interventions or disorders). We identifi ed three broad platforms to deliver interventions for MNS disorders: population, community, and healthcare platforms. Although a fair amount of good evidence from high-income countries exists in support of interventions across these platforms and along the continuum of primary, secondary, and tertiary prevention, the evidence base is far less robust for low-income and middle-income countries. Recom mendations for best practice interventions and good practice interventions for these platforms are set out in the table in fi gure 2. Best practice interventions were identifi ed on the basis of evidence for their eff ectiveness and contextual acceptability and scalability in low-income and middle-income countries, plus evidence of their cost-eff ectiveness, at least in high-income countries; good practice interventions were identifi ed on the basis of suffi cient evidence of their eff ectiveness in high-income countries or promising evidence of their eff ectiveness in low-income and middle-income countries, or both. That evidence of cost-eff ectiveness does not exist for most interventions in low-income and middle-income countries refl ects the absence of evidence rather than the absence of cost-eff ectiveness.
Population platform interventions typically apply to the entire population and primarily address the promotion of population mental health, prevention of MNS disorders, and demand side barriers such as stigma. Best practice packages include legislative and regulatory measures to restrict access to means of selfharm or suicide (notably pesticides) and reduce the availability of and demand for alcohol (eg, through increased taxes on alcohol products). Good practice packages include interventions aimed at raising mental health literacy and reducing stigma and discrimination. The criminal justice system off ers an important channel for delivery of interventions for a range of MNS disorders, notably those associated with alcohol and illicit drug use, behaviour disorders in adolescents, and the psychoses. Other preventive and promotion interventions do not require such a population-wide approach and are best delivered by targeting a group of people in the community who share a certain characteristic or are part of a particular setting; this platform is referred to as the community. Best practice packages at the community level include life-skills training to build social and emotional competencies in children and adolescents, and good practice packages include parenting programmes for parents with infants to promote early child development. Several other good practice packages are reported in fi gure 2.
The health-care platform comprises three specifi c delivery channels: self-management and care, primary health care, and hospital care. Examples of best or good practice packages for self-care include the self-management of disorders, such as migraine, and web-based psychological therapy for people with depression and anxiety disorders, increasingly enabled by internet and smartphone-based delivery. At the primary health-care level, a range of detection and diagnostic measures as well as the psychological and pharmacological management of disorders, including depression, anxiety disorders, migraine, and alcohol and illicit drug use disorders, can be eff ective, as can continuing care for severe disorders such as epilepsy or psychosis. The recommended delivery model is that of collaborative stepped care, in which patient care is coordinated by a primary health-care-based, The 686 Project: China 30 The Central Government Support for the Local Management and Treatment of Severe Mental Illnesses Project was initiated in 2004 with the fi rst fi nancial allotment of ¥6·86 million (US$829 000 in 2004), as a result of which, it was subsequently referred to as the 686 Project. Modelled on WHO's recommended method for integration of hospitalbased and community-based mental health services, this programme provides care for a range of severe mental disorders through the delivery of community-based packages by multidisciplinary teams. The interventions are functionality oriented and are delivered through free outpatient treatment through insurance coverage (New Rural Cooperative Medical Care system) along with subsidised inpatient treatment for poor patients. The programme covered 30% of the Chinese population by the end of 2011. Programme evaluation showed improved outcomes for the more than 280 000 registered patients as the proportion of patients with severe mental illnesses who did not suff er a relapse for 5 years or longer increased from a baseline of 67% to 90% along with large reductions in the rates of so-called creating disturbances and causing serious accidents. The programme investment by the Chinese Government amounted to ¥280 million in 2011, and its key innovations were the increase in the availability of human resources, including both the involvement of non-mental-health professionals and intensive capacity building, which have increased the number of psychiatrists in the country by one-third.
The National Depression Detection and Treatment Programme (Programa Nacional de Diagnóstico y Tratamiento de la Depresión): Chile
The National Depression Detection and Treatment Programme is a national mental health programme in Chile that integrates detection and treatment of depression in primary care. The programme is based on the scaling up of an evidence-based collaborative stepped-care intervention in which most patients diagnosed with depression are provided drugs and psychotherapy at the primary care clinics, whereas only severe cases are referred to specialists. Launched in 2001, the programme operates through a network of 500 primary care centres and presently covers 50% of Chile's population. A large number of psychologists have been added to the primary care, with a 344% increase between 2003 and 2008. Enrolment of the patients has grown steadily, with about 100 000-125 000 patients starting treatment each year from 2004 to 2006, and nearly 170 000 patients starting treatment in 2007. Nationwide implementation of the programme has led to a greater use of health services by women and the less educated people, contributing to reduced health inequalities. The programme's success can be attributed to the use of an evidence-based design that was made available to policy makers, teamwork and proactive leadership, strategic alliances across sectors, sustained investment and ringfencing new and essential fi nancial resources, programme institutionalisation, and sustained development of human resources that can implement the programme.
Building back better: Burundi 31
Civil war in the last decade of 20th century and fi rst decade of this century resulted in widespread massacres and forceful migrations and internal displacement of about 1 million individuals in Burundi. To address this humanitarian crisis, HealthNet Transcultural Psychosocial Organization (TPO) started providing mental health services in Burundi in 2000 when the then Ministry of Public Health had no mental health policy, plan, or mental health unit and almost all the psychiatric services were provided by one psychiatric hospital. HealthNet TPO fi rst assessed the needs and then built a network of psychosocial and mental health services in communities in the national capital, Bujumbura, and in seven of the country's 17 provinces. A new health worker cadre, the psychosocial worker, played a pivotal role in the delivery of these services. Substantial progress has been made in the past decade, with the government now supplying essential psychiatric drugs through its national drug distribution centre, and outpatient mental health clinics are established in several provincial hospitals. From 2000 to 2008, more than 27 000 people were helped by the newly established mental health and psychosocial service. Between 2006 and 2008, the mental health clinics in the provincial hospitals registered almost 10 000 people who received more than 60 000 consultations. Most (65%) of these people had epilepsy. In 2011, funding from the Dutch Government enabled HealthNet TPO and the Burundian Government to initiate a 5-year project aimed at strengthening health systems. One of the project's components is the integration of mental health care into primary care using WHO's Mental Health Gap Action Programme (mhGAP) guidelines. The government has now established a National Commission for mental health, and appropriate steps are being taken to support provision of mental health care in general hospitals and followup within the community. non-specialist case manager who performs a range of tasks including screening, provision of psychosocial interventions, and proactive monitoring, liaising closely with and acting as a link between the patient, the primary care doctor, and specialist services. 22, 26 At the hospital level, fi rst-level hospitals, typically district hospitals, can off er a range of medical care services that provide integrated care for people with MNS disorders by implementing the same packages as recommended for the primary health-care channel, particularly in those domains where MNS disorders frequently co-occur, such as in maternal health, other non-communicable diseases, and HIV. [27] [28] [29] In specialist services, which might either be off ered within fi rst-level hospitals or in separate specialist hospitals (such as psychiatric hospitals or alcohol and illicit drug treatment centres), interventions focus on the diagnosis and management of complex, refractory, and severe cases of MNS disorders, for example of psychosis, epilepsy, or alcohol use disorders. A small minority of individuals with MNS disorders would need ongoing care in community-based residential facilities because of their disability and lack of alternative sources of care and support. Communityoutreach teams that can provide variable levels of intensity of care appropriate for the individual's needs have a crucial role because their support enables these individuals to function in an independent and supported way, in the community, alongside close liaison with general primary health-care services and other social and criminal justice services.
In humanitarian contexts and emergency-aff ected populations, such as those arising from confl ict or natural disaster, the humanitarian aid and emergency response platform is another delivery channel for much-needed mental health care. These populations are at an increased risk of MNS disorders, which can overwhelm the local capacity to respond, particularly if the existing infrastructure or health system was already weak or might have been rendered dysfunctional as a result of the emergency situation. There is a heightened need to identify and allocate resources for the provision of mental health care and psychosocial support in these settings, both for people with disorders induced by the emergency and for people with pre-existing disorders. In several countries, such emergencies have actually provided opportunities for systemic change or service reform in public mental health care (panel 2). 33 Alongside eff orts to improve levels of contact coverage and bridge the treatment gap for people with MNS disorders, it is imperative to also enhance the quality of service delivery. Quality of care should not be subservient to the quantity of available and accessible services, not least since robust quality improvement mechanisms ensure effi cient use of limited resources, and good quality services build people's confi dence in health care, thereby fuelling the demand and increasing use of preventive and treatment interventions.
How much will it cost? Universal health coverage for MNS disorders
For successful and sustainable scale-up of eff ective interventions and innovative service-delivery strategies (such as task-sharing and collaborative care), decision makers need not only evidence of an intervention's eff ect on health, but also their costs and cost-eff ectiveness. Even when this cost-eff ectiveness evidence is available, the question remains of whether or how an intervention might confer wider economic and social benefi ts to households or society, such as restored productivity, reduced medical impoverishment, or greater equality. The methods used for our economic analyses included a review of existing cost-eff ectiveness evidence and exploratory analyses of the distributional and fi nancial protection eff ects of interventions (appendix p 2).
A small but growing economic evidence base exists to inform decision making in low-income and middle-income settings; this evidence base is mainly focused on the treatment of specifi c disorders such as epilepsy, alcohol use disorders, depression, and schizophrenia. Analysis undertaken at the global level (Panel 2 continued from previous page) Suicide prevention through pesticide regulation: Sri Lanka 32 In Sri Lanka as well as in other Asian countries, pesticide self-poisoning is one of the most common methods of suicide. Suicide rates in Sri Lanka increased eight times from 1950 to 1995, and the country had the highest rate of suicide worldwide (about 47 per 100 000 population) during this period. A series of policy and legislative actions during this time reduced the suicide rates. Findings from an ecological analysis 32 of trends in suicide and risk factors for suicide in Sri Lanka from 1975 to 2005 suggests that the marked decrease in Sri Lanka's suicide rates in the mid-1990s coincided with the culmination of a series of legislative activities that systematically banned the most toxic pesticides that had been responsible for most pesticide deaths in the preceding two decades. The Registrar of Pesticides banned methyl parathion and parathion in 1984 and gradually phased out all the remaining class I (the most toxic) organophosphate pesticides during the following years, culminating in July, 1995, with bans on the remaining class I pesticides monocrotphos and methamidophos. By December, 1998, endosulfan (a class II pesticide) was also banned as farmers had substituted class I pesticides with endosulfan. By 2005, suicide rates had been halved to about 25 per 100 000 population. This case study underlines the fact that, in countries where pesticides are commonly used in acts of self-poisoning, regulatory controls on the sale of the most toxic pesticides could have a favourable eff ect on suicide.
by WHO, updated to 2012 values for DCP-3, reveals a marked variation in the cost per DALY averted, not only between diff erent regions of the world but also between diff erent disorders and interventions; fi gure 3 shows the range for the most cost-eff ective intervention identifi ed for each of the four disorders mentioned above (appendix p 3). 18, 23 Brief interventions for harmful alcohol use and treatment of epilepsy with fi rst-line antiepileptic drugs fall towards the lower (more favourable) end of cost per DALY averted, whereas community-based treatment of schizophrenia with fi rst-generation drugs and psychosocial care falls towards the upper end of cost per DALY averted. Estimates from comparable national studies in Brazil, Nigeria, and Thailand, again adjusted to 2012 values, fall in the range of $100-2000 per DALY averted. [34] [35] [36] With the exception of an analysis of alcohol-demand reduction measures-which estimated that one DALY could be averted for as little as $200-400 through increases in excise taxes on alcoholic beverages and for $200-1200 through comprehensive advertising bans or reduced availability of retail outlets 37 -hardly any published evidence exists on the cost-eff ectiveness of population-based or community-level strategies in or for low-income and middle-income settings.
The combined cost of implementing these alcoholcontrol measures in low-income and middle-income settings has been estimated to be $0·10-0·30 per head. 37 A new cost analysis for DCP-3 estimates that a schoolbased life-skills programme would cost $0·05-0·25 per head (appendix p 5). The annual cost of delivering a defi ned package of cost-eff ective interventions for schizophrenia, depression, epilepsy, and alcohol use disorders in two WHO sub-regions (one in sub-Saharan Africa, the other in south Asia) has been estimated to be $3-4 per head. 23 In more affl uent regions or in uppermiddle-income countries, the cost of such a package is expected to be at least double this amount (appendix p 3).
Beyond health improvement, other important goals or attributes of health systems can be considered, including equity and fi nancial protection. Since many MNS disorders run a chronic and disabling course, often go undetected, and are regularly omitted from essential packages of health care or insurance schemes, they pose a direct threat to the wellbeing and economic viability of households as a result of private out-of-pocket expenditures on health services and goods as well as diminished production or income opportunities. 38 It is therefore incumbent upon governments to ensure that intervention costs are largely met through fi nancial protection measures such as health insurance schemes. In the many low-income and middle-income settings in which rates of service availability and uptake remain very low, however, enhanced fi nancial protection measures alone will not move the population of people with MNS disorders substantially towards a goal of universal health coverage. For that goal to be progressively realised, fi nancial coverage of people with MNS disorders needs to be accompanied by substantially scaled up service coverage. 39
How to scale up? Health system barriers and opportunities
Despite the evidence summarised in the preceding sections, most low-income and middle-income countries are taking relatively little action to address the health care and other needs of people with MNS disorders. Perhaps the most important reason for this failure to act is the overall poor political commitment to MNS disorders, as evident from the fact that less than 1% of the health budget in most low-income and middleincome countries is allocated to mental health. 40 Similarly, despite the evidence-based calls to action to scale up services for almost a decade, 41 less than 1% of development assistance for health is devoted to mental health care. 42 Key reasons for the absence of political will and consequently low levels of resource allocation include the low demand for mental health-care interventions (in part due to low levels of mental health literacy and high levels of stigma associated with MNS disorders); the absence of technically sound leadership in designing and implementing evidence-based programmes; the absence of adequate absorptive capacity in the existing health-care system; competing policy priorities and vested interests (eg, in relation to the alcohol beverage and pharmaceutical industry and the medical profession); the absence of eff ective agency and advocacy by aff ected people; and the persisting (2006); 18 Chisholm and Saxena (2012 belief in the importance of hospital-based specialised models of care, which continue to absorb disproportionate amounts of the already meagre budgetary allocations for this sector. 25 To add to this list is the reality that the evidence synthesised in this paper has limitations, particularly the substantial gaps in the evidence in support of some interventions in lowincome and middle-income countries and limited eff ectiveness of the best available interventions for some disorders. To address this formidable list of barriers, the scaling up of interventions for people with MNS disorders will require an approach that embraces public health principles, systems thinking, and a whole-of-government perspective, as has been shown by several countries (panel 2). Key strategies necessary for health-system strengthening include: the mainstreaming of a rights-based perspective throughout the health system and ensuring health policies, plans, and laws are updated to be consistent with international human rights standards and conventions; implementation of multi-component initiatives to address stigma, enhancement of mental health literacy and demand for care, and mobilisation of people with the disorders to support each other and be 
Proposed indicators
• Routine data and reports at national level available on core set of mental health indicators • Annual reporting of national data on numbers of deaths by suicide eff ective advocates; engagement of other key sectors that work to improve services for people with MNS disorders, notably the social care, non-governmental organisations, private sector, criminal justice, education, and indigenous medical sectors, as they may have complementary roles; provision of inpatient care in the form of general or district hospital units rather than stand-alone psychiatric hospitals; the creation of a non-specialist cadre for human resources that can be case managers and coordinate the delivery of collaborative care in primary care and other health-care platforms; ensuring the supply of essential medicines at relevant platforms; and investment in research across the translational continuum (from basic scientifi c discoveries to eff ective clinical applications to interventions for improving public health). Financing options could include the raising and diversion of income taxes on unhealthy products (such as alcohol and tobacco); emphasis on the use of low-cost generic drugs throughout the health-care system; and reallocation of expenditure on ineff ective or low-value interventions (such as irrational use of benzodiazepines and vitamins in primary care). Finally, the embedding of health indicators for MNS disorders within national health information and surveillance systems will be important so that progress and achievements can be monitored and assessed. 43 The WHO Comprehensive Mental Health Action Plan 44 off ers a clear roadmap for countries at any stage of the journey to scale up eff orts. Some WHO regions (such as the Eastern Mediterranean) have adapted this new policy instrument to initiate consultations with international experts and regional policy makers to develop frameworks for action (panel 3) across all four domains of the Plan, along with priority interventions and indicators for assessment of progress. 45
Time to act, now
MNS disorders account for a substantial proportion of the global disease burden. This burden has increased dramatically since 1990 and is expected to rise in line with the epidemiological transition from infectious disease to non-communicable disease, with demographic transition in low-income and middle-income countries, and with the increase in the prevalence of several social determinants associated with these disorders. New analyses presented here suggest that the mortalityassociated disease burden is very large and previously underestimated. We have also summarised evidence of several eff ective treatment and prevention interventions that are feasible to implement across diverse socioeconomic and cultural settings for a range of priority MNS disorders. A very relevant aspect of these disorders is their propensity to strike early in life, which is a key factor behind their large contribution to the global burden of disease. Although several important health-system barriers need to be addressed to scale up the recommendations outlined in this paper, country case studies (panel 2) show that the most important driver of change is political will and commitment in countries and development agencies to allocate the necessary resources and provide technical leadership. The analyses presented in this DCP-3 volume will be synthesised over the coming months along with the fi ndings and recommendations of eight other volumes, with a view to inform ongoing deliberations around the implementation of the Sustainable Development Goals and other policy agendas. The evidence from this volume alone makes a compelling case to scale up interventions to address the avoidable toll of suff ering caused by MNS disorders, not least among the poorest people and least resourced countries in the world. Although our analyses have presented the strong public health and economic evidence to support this investment, a moral case must ultimately be made for the scaling up of health care for the hundreds of millions of people whose health-care needs have been systematically neglected and whose basic human rights routinely denied. 46 The time to act on this evidence is therefore now.
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